Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of therapeutic strategies with cholinesterase inhibitors: stop or still (SOS) trial
2017-000569-61Phase 4Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Oct 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of donepezil, galantamine and rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Primary composite outcome at 2 years. Started Oct 2017; status: active.
02
Drugs
donepezilgalantaminerivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-000569-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000569-61.